TVIA Trademark

Trademark Overview


On Wednesday, April 11, 2018, a trademark application was filed for TVIA with the United States Patent and Trademark Office. The USPTO has given the TVIA trademark a serial number of 87872626. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, May 21, 2019. This trademark is owned by Vivera Pharmaceuticals. The TVIA trademark is filed in the Pharmaceutical Products category with the following description:

Cardiovascular pharmaceuticals; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of endocannabinoid; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of orodispersable tablets and/or sublingual tablets that facilitate the delivery of pharmaceutical preparations; Human vaccine preparations; Nutraceuticals for use as a dietary supplement; Oral vaccine preparations; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting met...
tvia

General Information


Serial Number87872626
Word MarkTVIA
Filing DateWednesday, April 11, 2018
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, May 21, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesCardiovascular pharmaceuticals; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of endocannabinoid; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of orodispersable tablets and/or sublingual tablets that facilitate the delivery of pharmaceutical preparations; Human vaccine preparations; Nutraceuticals for use as a dietary supplement; Oral vaccine preparations; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of the cardiovascular system, the circulatory system, the digestive system, the excretory system, the endocrine system, the integumentary system, the exocrine system, the lymphatic system, the immune system, the muscular system, the nervous system, the renal system, the urinary system, the reproductive system and/or the skeletal systerm; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical solutions used in dialysis; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 19, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameVivera Pharmaceuticals
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92614

Trademark Events


Event DateEvent Description
Tuesday, May 21, 2019ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, May 21, 2019ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, April 22, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, April 22, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, October 23, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 23, 2018NON-FINAL ACTION E-MAILED
Tuesday, October 23, 2018NON-FINAL ACTION WRITTEN
Tuesday, October 16, 2018ASSIGNED TO EXAMINER
Tuesday, May 1, 2018ASSIGNED TO EXAMINER
Thursday, April 19, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, April 14, 2018NEW APPLICATION ENTERED IN TRAM